#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Fragile X syndrome Non-small cell lung cancer metastatic Brain stem glioma Cerebral arteriovenous malformation haemorrhagic Acute graft versus host disease in intestine Chronic lymphocytic leukaemia recurrent Alagille syndrome Measles Depression Frontotemporal dementia Juvenile chronic myelomonocytic leukaemia Oesophageal squamous cell carcinoma stage III Leiomyosarcoma metastatic Spinal cord injury Rhabdomyosarcoma More trials…

    Learn about Rare Diseases

    Uterine leiomyosarcoma – Life with Disease Marfan’s syndrome – Trials in Disease VEXAS syndrome – Life with Disease Glycogen storage disease type V – Trials in Disease Choroid melanoma – Treatment Piriformis syndrome – Diagnostics Haemophilia A without inhibitors – Life with Disease Fabry’s disease – Diagnostics Haemophilia A without inhibitors – Trials in Disease Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tropicamide Metamizole RUBIDIUM CHLORIDE OMEGA-3-ACID ETHYL ESTERS 90 Cariprazine Hydrochloride Poa Pratensis GSK3862995B ULTEVURSEN Prasugrel Vb10.16 Dabigatran Etexilate Acetylcysteine Amide Losartan Potassium Chloride Ion Simoctocog Alfa Rifamycin Sodium Charcoal, Activated Cetrimide Technetium (99Mtc) Db-1303 More therapies…

    Learn about Your Condition

    Vitiligo Biliary adenoma Langerhans' cell histiocytosis Endometrial cancer metastatic Papilloma viral infection Reperfusion injury Schizophrenia Rectal cancer Acromegaly Ligament sprain Cystic fibrosis lung Hyperparathyroidism secondary Peripheral artery thrombosis Systemic sclerosis pulmonary Renal cell carcinoma stage IV More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Bladder transitional cell carcinoma

  • Study of RO7247669, Tiragolumab, and Atezolizumab for Patients with Untreated Advanced Urothelial Cancer Ineligible for Platinum Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Ro7247669
    • Tiragolumab
    • Atezolizumab
    Denmark France Germany Greece Italy Poland +1

  • Study of TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Not Undergoing Radical Cystectomy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Cetrelimab
    • Cisplatin
    • Gemcitabine
    Austria Belgium Czechia France Germany Greece +4

  • Study on Enfortumab Vedotin and Pembrolizumab for Patients with Advanced Urothelial Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma urethra
    • Transitional cell cancer of the renal pelvis and ureter
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Enfortumab Vedotin
    • Pembrolizumab
    France

  • Study of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Enfortumab Vedotin
    • Carboplatin
    • Cisplatin
    Belgium Czechia Denmark France Germany Hungary +4

  • Study comparing enfortumab vedotin versus chemotherapy combination (docetaxel, paclitaxel, vinflunine) in patients with previously treated advanced or metastatic bladder cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Vinflunine
    • Enfortumab Vedotin
    • Docetaxel
    Portugal Spain

  • Study of Pembrolizumab and Sacituzumab Govitecan for Patients with Muscle-Invasive Bladder Cancer Unable or Unwilling to Use Cisplatin-Based Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Pembrolizumab
    Italy
Previous Page
1 … 3 4 5 6
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!